Breaking Down Double Medical Technology Inc. Financial Health: Key Insights for Investors

Curious whether Double Medical's recent performance justifies investor interest? The company posted nine‑month sales of CNY 1,876.25 million (up 22.7% YoY to Sept 30, 2025) after a CNY 2,118.86 million full‑year 2024 revenue (+39.1% YoY), delivered nine‑month net income of CNY 424.65 million (a 77% increase) with EPS from continuing operations at CNY 1.0444, and reported Q2 2025 gross profit of CNY 441.21 million with a gross margin of 66.84% even as FY2024 gross margin declined to 66.75% from 76.72%; liquidity remains robust with CNY 1.35 billion in cash and short‑term investments, a current ratio of ~4.5x and free cash flow of CNY 171.84 million (+174.1% YoY), while leverage is conservative (debt‑to‑equity ~8.4%, total debt CNY 288.79 million) and the market values the company at CNY 20.3 billion (share price CNY 48.99) with a FY2024 P/E of 35.86 and EV/EBITDA of 21.49 - read on to unpack valuation, risks, and the growth drivers behind these figures.

Double Medical Technology Inc. (002901.SZ) - Revenue Analysis

• Nine months ended Sept 30, 2025: revenue CNY 1,876.25 million, up 22.7% vs CNY 1,529.26 million in same period 2024.
• Full year 2024 revenue: CNY 2,118.86 million, up 39.1% vs CNY 1,524.73 million in 2023.
• Q2 2025 quarterly revenue: CNY 660.10 million; gross profit CNY 441.21 million; gross margin 66.84%.
• Five-year annualized revenue growth: ~3.9%.
• Revenue per share: CNY 5.15 (2024) vs CNY 3.68 (2023).
• Cost of revenue: CNY 710.15 million (2024) vs CNY 492.24 million (2023), driving gross margin down from 76.72% to 66.75%.

• Year-over-year acceleration: FY2024 growth of 39.1% vs FY2023, and 9M2025 growth of 22.7% vs 9M2024 - indicates continuing demand momentum.
• Margin dynamics: gross margin compressed from 76.72% (reported peak) down to ~66.75% in 2024 due to higher cost of revenue; Q2 2025 margin stabilized at 66.84%.
• Per-share efficiency rose meaningfully in 2024, with revenue per share improving to CNY 5.15 from CNY 3.68 in 2023.
• Medium-term growth: five-year annualized revenue of ~3.9% signals a longer-term steady trend despite recent episodes of faster expansion.

Double Medical Technology Inc. (002901.SZ) - Profitability Metrics

• Strong year-over-year profitability acceleration in 2024 driven by both operating performance and margin expansion.
• Continued momentum into 2025 YTD (nine months) with substantial net income and EPS growth versus the same period in 2024.

• Net income surged 505% from CNY 58.96M in 2023 to CNY 356.80M in 2024, signaling a major turnaround.
• Operating income jumped from CNY 19.47M in 2023 to CNY 334.38M in 2024, indicating marked operational efficiency gains.
• Nine months ending Sept 30, 2025: net income CNY 424.65M, up 77% vs CNY 239.88M in 9M 2024; EPS rose to CNY 1.0444 from CNY 0.5794.
• Margin and ROE improvements (net profit margin 16.7% and ROE 11.6% in 2024) reflect better capital utilization and pricing/ cost control.

Double Medical Technology Inc. (002901.SZ) - Debt vs. Equity Structure

Key balance-sheet metrics as of June 30, 2025 and fiscal 2024 coverage highlight a conservative leverage profile but operating challenges affecting interest coverage.

• Total debt: CNY 288.79 million (6/30/2025).
• Total equity: CNY 3.44 billion (6/30/2025).
• Debt-to-equity ratio: 8.4% (6/30/2025).
• Total assets: CNY 4.6 billion; total liabilities: CNY 1.1 billion (6/30/2025).
• Total liabilities / total assets: ~23.9% (6/30/2025).
• Cash & short-term investments: CNY 1.35 billion (6/30/2025).
• Interest coverage (FY2024): -17.2x (negative, indicating operating losses relative to interest expense).
• Equity growth: CNY 2.86 billion in 2022 → CNY 3.44 billion in 2025.

Liquidity (CNY 1.35 billion in cash and short-term investments) combined with a low debt burden supports ability to meet near-term obligations despite a negative interest coverage driven by 2024 operating performance. For additional corporate context, see Mission Statement, Vision, & Core Values (2026) of Double Medical Technology Inc.

Double Medical Technology Inc. (002901.SZ) - Liquidity and Solvency

• Cash and short-term investments (as of June 30, 2025): CNY 1.35 billion.
• Current ratio (as of June 30, 2025): ~4.5x - indicates ample coverage of current liabilities by current assets.
• Quick ratio (as of June 30, 2025): ~3.2x - strong immediate liquidity after excluding inventories.
• Operating cash flow: CNY 500 million in FY2024, up from CNY 300 million in FY2023.
• Free cash flow: CNY 171.84 million in FY2024, up 174.1% from CNY 62.7 million in FY2023.
• Debt maturity profile: well-managed with no significant repayments due in the next 12 months.

Double Medical Technology Inc. (002901.SZ) - Valuation Analysis

• Market cap (19-Dec-2025): CNY 20.3 billion
• Share price (19-Dec-2025): CNY 48.99
• P/E (FY2024): 35.86 - elevated relative to typical healthcare peers, signaling growth expectations priced in
• P/S (FY2024): 5.99 - high revenue multiple, reflecting strong margin or growth premium
• EV/EBITDA (FY2024): 21.49 - indicates the market values operating cash flow strongly
• 52-week range: CNY 28.70 - CNY 66.50 - demonstrates notable volatility
• Analyst consensus: Strong Buy; average 12-month target CNY 43.82 - implies downside from current price

• Valuation context: P/E ~36 and EV/EBITDA ~21.5 place the company in a premium bucket; investors are pricing expected above-market growth or superior margins.
• Risk signal: Analyst price target (CNY 43.82) vs. market price (CNY 48.99) suggests limited upside or short-term downside risk despite a Strong Buy consensus.
• Volatility note: 52-week spread (CNY 28.70-66.50) implies trading can be driven by news, clinical results, or policy changes.

Double Medical Technology Inc. (002901.SZ) - Risk Factors

• Interest coverage: -17.2x for fiscal year 2024, indicating inability to cover interest from operating earnings and elevated default/liquidity risk.
• Share price performance: -42% over the past five years, underperforming broader markets and potentially impairing investor confidence and access to equity capital.
• Leverage vs. liquidity: Debt-to-equity ratio of 8.4% (low leverage) contrasted with negative interest coverage, creating a mismatch that signals possible short-term liquidity strain despite modest balance-sheet debt.
• Profitability pressure: Gross profit margin fell from 76.72% in 2022 to 66.75% in 2024, reflecting rising input costs, margin compression, or pricing pressure in core products/services.
• Operating performance volatility: Operating income has fluctuated year-to-year with a pronounced decline in 2023, suggesting operational challenges, cyclical demand, or one-off losses affecting core operations.
• Market volatility: 52-week trading range CNY 28.70-CNY 66.50, showing high share-price volatility that may deter risk-averse investors and complicate valuation.

• Counterparty & credit risk: Negative interest coverage raises lender scrutiny and could result in tighter credit terms or higher financing costs.
• Margin sustainability risk: Declining gross margins may force pricing adjustments, cost-cutting, or product mix changes that could impact growth.
• Execution risk: Fluctuating operating income and the 2023 downturn point to execution and operational-risk exposure (manufacturing, R&D, supply chain).
• Market/liquidity risk: Significant share-price volatility and multi-year underperformance may limit secondary market liquidity for large shareholders.
• Event risk: Unexpected macro shocks, regulatory changes, or slower product adoption could exacerbate existing liquidity and profitability pressures.

Double Medical Technology Inc. (002901.SZ) - Growth Opportunities

Double Medical Technology Inc. (002901.SZ) shows several quantitative indicators pointing to robust growth capacity and improving financial efficiency, underpinned by meaningful cash generation and market valuation that support expansion.

• Analyst forecasts: earnings growth of 22.6% p.a. and revenue growth of 18% p.a., signaling strong top- and bottom-line momentum.
• Return on equity (ROE) projected to reach 19.9% within three years, implying improving capital efficiency and profitability enhancement.
• Market capitalization: CNY 20.3 billion, providing balance-sheet firepower for R&D, M&A, and capacity expansion.

• Revenue efficiency: revenue per share rising from CNY 3.68 in 2023 to CNY 5.15 in 2024 reflects improved unit economics and scaling benefits.
• Cash flexibility: a 174.1% YoY increase in free cash flow supports capex for capacity, accelerated product development, and selective acquisitions.
• Valuation and investor returns: a CNY 28.70-66.50 52-week trading band highlights material upside potential for capital appreciation if operational targets are met.

Strategic implications for investors include prioritizing monitoring of execution against the 18-22.6% growth runway, ROE improvement to ~19.9%, and continued conversion of revenue gains into free cash flow. Additional context on corporate direction is available here: Mission Statement, Vision, & Core Values (2026) of Double Medical Technology Inc.